Sermorelin vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | LL-37 (Cathelicidin) |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |
What They Have in Common
Both Sermorelin and LL-37 (Cathelicidin) are commonly used for: